Atreca, Inc. announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%. Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0901 USD | -3.16% | -0.11% | -31.74% |
17/04 | North American Morning Briefing : Stock Futures -2- | DJ |
10/04 | North American Morning Briefing : Traders Await -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.74% | 3.57M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BCEL Stock
- News Atreca, Inc.
- Atreca, Inc. Reduces its Workforce by Approximately 40%